BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 9293788)

  • 1. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
    Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
    J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
    Muratet JP; Daver A; Minier JF; Larra F
    J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
    J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
    Silberstein EB
    J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
    Dam HQ; Kim SM; Lin HC; Intenzo CM
    Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
    Moser E; Fritsch S; Braun S
    Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up of differentiated thyroid cancer.
    Pacini F
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
    Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
    Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
    Roelants V; Nayer PD; Bouckaert A; Beckers C
    Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.